Gilteritinib in combination with venetoclax, low‐dose cytarabine and actinomycin D for relapsed or refractory FLT3‐mutated acute myeloid leukaemia.

Summary: We have conducted a retrospective, single‐centre analysis of 20 patients with relapsed or refractory FLT3‐mutated acute myeloid leukaemia (FLT3m AML) who received a salvage quadruplet regimen consisting of gilteritinib, venetoclax, low‐dose cytarabine and actinomycin D (G‐ACTIVE). G‐ACTIVE resulted in a 95% (19/20) overall response rate and 75% (15/20) complete remission and complete remission with an incomplete platelet recovery (CR + CRp) rate. Out of 13 transplant‐eligible patients, 11 (86%) proceeded to an allogeneic stem cell transplantation. The median overall survival and relapse‐free survival after G‐ACTIVE were 32 and 12.9 months respectively. The Day 60 mortality rate was 15%. [ABSTRACT FROM AUTHOR]